Member Info for Jarv55

https://twitter.com/carlsmythe/status/1325898928726953985?s=20

Magmanus you haven't done any research at all have you? Read the circular.

The scalaibilty is massive here
THE NHS
Private hospitals
Doctors surgeries
Bio companies GSK Astrazenica Ncyt etc
Councils
Schools
Manufacturing Companies
Universities
Old residential homes
Supermarkets
That is just the UK
Then there is the licencing of the teck to other mask manufacturers.

https://twitter.com/LilianGreenwood/status/1325073158324563969

Well done Cardan have sent the company a few suggestions myself they are excellent at communicating.

18 Of Braveheart’s shareholders, only Trevor Brown will have an indirect interest in RMS over 5 per cent. following the Acquisition.

Shareholder Number of shares % shares held Trevor Brown 8,588,288 24.75% DC Thomson Ltd 2,258,490 6.50% AG Simpson 1,254,341 3.61% W Rehman 1,105,440 3.18%

Braveheart and Mr. Trevor Brown Braveheart is a fund management and strategic investor group that makes calculated investments in advanced technology companies it judges will outperform market expectation. The group was formed in 1997 and, since 2007, has been quoted on AIM as BRH.L. Along with financial investment, Braveheart also provides expert advice to the companies it backs and helps them make decisions around operations, strategy and risk. Braveheart’s aim is to return cash to shareholders while increasing the value of their shares. Braveheart is incorporated in Scotland with the company number SC247376, and its registered office is at 1 George Square, Glasgow, Scotland, G2 1AL. In addition to its existing 25.79 per cent. interest in the Company, it also has strategic and portfolio investments in a number of private businesses including Gyrometric Systems Limited where RMS has a controlling shareholding. Braveheart’s largest shareholder with a 24.75 per cent. shareholding is Mr. Trevor Brown who is also an Executive Director of RMS as well as being Chief Executive Officer of Braveheart. No other Director of RMS holds any interest in Braveheart. The remainder of the shares in Braveheart are held by a number of high net worth individuals, family and investment trusts, pension funds and private individual investors. Please see below for a table of Braveheart’s significant shareholders:

Following consultation by the Company, the Panel has confirmed that Mr Trevor Brown, Dr. G Cave and Braveheart Investment Group plc, constitute a 'concert party' under the Takeover Code. Details of the individual Shareholders who qualify as the Concert Party and further information on the members of the Concert Party are set out in paragraph 4 of this Part II. As at the date of this Circular, Braveheart holds an interest in 199,637,590 Ordinary Shares representing 25.79 per cent. of the Existing Ordinary Shares and voting rights of the Company. As at the date of this Circular, Dr. Cave does not hold an interest in the Existing Ordinary Shares and voting rights of the Company. As at the date of this Circular, Mr. Trevor Brown does not hold a direct interest in the Existing Ordinary Shares and voting rights of the Company. Therefore, the Concert Party’s total holding of the Existing Ordinary Shares and voting rights of the Company is 199,637,590 Ordinary Shares representing 25.79 per cent. of the Company. On Completion of the Acquisition, and prior to the Braveheart Warrants having been exercised, Braveheart will hold 509,992,405 Ordinary Shares, which will represent 37.12 per cent. of the Enlarged Issued Share Capital and total voting rights of the Company. Dr. Cave will hold 289,645,185 Ordinary Shares, which will represent 21.08 per cent. of the Enlarged Issued Share Capital and total voting rights of the Company. Therefore in total the Concert Party will hold 799,637,590 Ordinary Shares, which will represent 58.20 per cent. of the Enlarged Issued Share Capital and total voting rights of the Company. Following Completion of the Acquisition and assuming only Braveheart exercises its 10 million warrants in full, which are exercisable immediately, Braveheart will hold 519,992,405 Ordinary Shares, which will represent 37.57 per cent. of the Potential Enlarged Issued Share Capital and total voting rights of the Company. Dr. Cave will hold 289,645,185 Ordinary Shares, which will represent 20.93 per cent. of the Potential Enlarged Issued Share Capital and total voting rights of the Company. Mr. Trevor Brown does not hold a direct interest in the Existing Ordinary Shares and voting rights of the Company.

Braveheart announces that on 6 November 2020 it exercised a total of 10 million options over ordinary shares in Remote Monitored Systems plc ("RMS") at an exercise price of 0.5p per share ("the RMS Option Shares") and an aggregate cost of £50,000. Braveheart has been advised that application will be made by the directors of RMS for the RMS Option Shares to be admitted to trading on the AIM market and that dealings are expected to commence on or about 13 November 2020.

Braveheart also announces that on 5 and 6 November 2020, it sold a total of 120 million ordinary shares in RMS at a weighted average price of 2.6265p per share, realising gross proceeds of approximately £3.15 million. The net funds receivable by Braveheart are primarily intended to fund the COVID-19 test project, as required and assuming it continues to deliver the results necessary to justify continuing the project, being conducted by Paraytec Limited through to a point where it is ready for commercial launch. Following these sales, Braveheart holds 389,992,405 RMS shares, representing 25.45 per cent. of the voting rights of RMS and following the admission to AIM of the RMS Option Shares will hold 399,992,405 RMS shares, representing 25.94 per cent. of the then enlarged voting rights of RMS.

7 3.Background to, reasons for and details of the AcquisitionPharm2Farm uses a patented process for producing and functionalising nanoparticles for various applications including human, animal and crop health. Unlike competing nanotechnology production processes, such as hydrothermal synthesis, Pharm2Farm’s process has the advantages of being highly efficient, using a small physical lab/factory footprint and is extremely scalable. Since Braveheart Investment Group acquired an interest in Pharm2Farm in July 2019, the team has moved into a new facility in MediCity Nottingham and more than doubled nanoparticle production capacity. Pharm2Farm’s strategy is focused on two markets:?Crop nutrition: Pharm2Farm has already received orders from key distributors in the UK and South Korea for its unique crop nutrition products. Pharm2Farm is specifically targeting the growing global hydroponics market where its water-soluble nutrients with high bioavailability have a clear competitive advantage. A number of trials are underway to explore further applications of Pharm2Farm formulations. ?Anti-viral Face Mask: Pharm2Farm is developing a nanotechnology enabled anti-viral face mask. Proof of concept and the design of a prototype is currently underway and expected to be completed by the end of the year. Once proven, Pharm2Farm will commence the commercial manufacture of masks in the UK. In addition Pharm2Farm’s modular platform technology and flat organisational structure provides the agility and flexibility to respond to the specific needs of each market segment. Hence, Pharm2Farm is able to capture very high value – low volume markets such as in electronics. Pharm2farm’s main competitor (Promethean) which has a large 1,000MT inefficient reactor requires large minimum order sizes to be profitable. Looking at the face mask market alone: global face mask market was valued at $1.52 billion in 2019 and is expected to grow by 4.4% CAGR reaching $2.45 billion in 2027. Pharm2Farm’s Innovate UK project is expected to produce a higher value anti- viral face mask prototype by December 2020. P2F had unaudited revenues of £11,979 and profit of £4,292 for the seven month period ending 31 March 2020. The directors of Braveheart believe that by combining the two shareholdings of P2F in RMS, and thereafter retaining a significant interest in RMS, the business prospects for P2F can be more rapidly exploited and resourced, thus enabling Braveheart to continue having an economic interest in P2F without the continuing requirement to fund P2F. The directors of Braveheart intend to retain the Consideration Shares for the foreseeable future

Dr Cave has kept all his shares

Some one is still selling

Do read the Circular https://wp-rms-2020.s3.eu-west-2.amazonaws.com/media/2020/10/19210809/Pharm-2-Farm-acquisition-circular.pdf

Devil its been tested in not one but two separate labs do read the rns.

https://www.prnewswire.co.uk/news-releases/face-mask-market-worth-3-0-billion-by-2025-exclusive-report-by-marketsandmarkets-tm--832236552.html

Hamodeh think the profit margins are much bigger

If I was Doctor Cave I would be contacting all the companies that have contracts with the government for testing. Ncyt, Odx, Tanner, Abbingdon Health, Randox etc they all have labs where you have to wear masks get selling to them.

https://twitter.com/DeborahMeaden/status/1322664797016645632

You can follow the progress here https://twitter.com/Pharm2Farm_org